BRD2 and COVID-19: These findings support the trend reported by Wolfe et al. who analyzed a similar UNOS data set but with a limited follow‐up time [21], and are in contrast to the results by Madan et al. who reported increased 6‐month and 1‐year mortality for recipients of HTs from active COVID‐19 donors (NAT positive within 2 days of procurement) compared to non‐COVID donors [6].